Emblica Fucus Chebula Extracts Mitochondrial Biogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective methods for addressing mitochondrial dysfunction, particularly mitochondrial DNA depletion, which is associated with various diseases and conditions including viral infections, aging, and energy-related issues.
Innovation Solution
Administration of a composition comprising emblica extract, fucus extract, and chebula extract, or their pharmaceutically acceptable forms or compounds with a similarity score of at least 95%, to treat or prevent viral infection-induced symptoms and mitochondrial dysfunction by inducing mitochondrial biogenesis and improving mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for viral infections, then viral symptoms are managed, but mitochondrial dysfunction and mtDNA depletion are not effectively addressed
Solution Approach 1:
The patent applies universality by developing a treatment composition that simultaneously addresses multiple conditions: viral infections, mitochondrial dysfunction, and mtDNA depletion. The composition comprising emblica extract, fucus extract, and chebula extract functions as a multi-functional therapeutic agent that can treat various symptoms including fatigue, muscle weakness, and respiratory issues associated with both viral infections and mitochondrial dysfunction, thereby resolving the contradiction between treating viral symptoms and addressing mitochondrial dysfunction.
2Reliability
If mitochondrial biogenesis is induced to treat mitochondrial dysfunction, then mitochondrial function improves, but inflammatory markers and circulating mtDNA levels increase
Solution Approach 1:
The patent applies the blessing in disguise principle by utilizing the increase in circulating mtDNA levels (which could be harmful) as a beneficial signal. The composition induces mitochondrial biogenesis, which naturally increases mtDNA circulation, but simultaneously reduces inflammatory markers through the anti-inflammatory properties of the extract components. This converts the potential harm of increased mtDNA into a beneficial indicator of mitochondrial regeneration while controlling inflammation.
3Reliability
If a composition with multiple extracts is used to treat mitochondrial dysfunction, then treatment effectiveness improves, but device complexity increases
Solution Approach 1:
The patent applies merging by combining three distinct natural extracts (emblica, fucus, and chebula) into a single integrated composition. Each extract contributes specific bioactive compounds that work synergistically: emblica provides antioxidants, fucus contributes to mitochondrial membrane stability, and chebula enhances mitochondrial biogenesis. This merged composition simplifies administration compared to using multiple separate treatments while maintaining enhanced effectiveness through synergistic interactions among the components.
Data Source
AI summary
Methods for treating or preventing viral infection-induced symptoms are disclosed. Methods for treating or preventing a viral infection are disclosed. Methods for treating or preventing mitochondrial dysfunction are disclosed. The viral infections include SARS-CoV-2, HIV, Influenza, and MERS. The methods include administering an emblica extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of an emblica extract, a fucus extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a fucus extract, or a chebula extract or a compound constituent of or having a similarity score of at least 95% with a compound constituent of a chebula extract.